Selectivity sets off $37M series A for mTOR company Aeovian

Selectivity data for Aeovian’s mTORC1 inhibitor attracted venBio, Sofinnova Investments to lead series A

Preclinical selectivity data for Aeovian’s mTORC1 inhibitor prompted venBio and Sofinnova Investments to co-lead the biotech’s $37 million series A after long eyeing the space.

“mTORC1 selective inhibition has been a Holy Grail target in big pharma for a long time,” venBio’s Richard Gaster told BioCentury. The

Read the full 460 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE